BeiGene Past Earnings Performance

Past criteria checks 0/6

BeiGene has been growing earnings at an average annual rate of 1.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 44.9% per year.

Key information

1.3%

Earnings growth rate

11.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate44.9%
Return on equity-24.8%
Net Margin-25.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BeiGene makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:49B Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2423,508-5,99312,22113,464
30 Jun 2422,504-3,80612,01313,534
31 Mar 2419,948-5,66411,58313,218
31 Dec 2317,452-6,25810,68412,624
30 Sep 2315,649-7,12810,23821,148
30 Jun 2313,139-12,5709,98517,935
31 Mar 2310,694-13,1669,01414,072
31 Dec 229,766-13,8208,81911,315
30 Sep 228,892-15,2918,9430
30 Jun 227,160-13,6008,0620
31 Mar 225,561-12,4247,0010
31 Dec 217,475-9,2646,2929,273
30 Sep 216,851-8,6415,7510
30 Jun 216,115-8,5695,0590
31 Mar 215,653-7,6454,4240
31 Dec 202,016-10,6083,9180
30 Sep 201,804-10,2683,6350
30 Jun 201,588-9,8523,3880
31 Mar 202,850-8,1083,1000
31 Dec 192,982-6,6052,7030
30 Sep 193,073-5,9232,2680
30 Jun 192,980-4,5701,7940
31 Mar 191,634-4,9451,5040
31 Dec 181,363-4,6351,3440
30 Sep 181,083-3,4681,0320
30 Jun 182,143-1,6117750
31 Mar 181,700-9235190
31 Dec 171,551-6064070
30 Sep 171,465-209290-34
30 Jun 170-1,2492210
31 Mar 173-1,0181770
31 Dec 167-8281400
30 Sep 1638-7269835
30 Jun 1647-581800
31 Mar 1652-445600
31 Dec 1557-371470
30 Sep 1535-214380
30 Jun 1566-182480
31 Mar 1573-162450
31 Dec 1481-113430
31 Dec 1367-45190

Quality Earnings: 49B is currently unprofitable.

Growing Profit Margin: 49B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 49B is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare 49B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 49B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 49B has a negative Return on Equity (-24.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 56 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.